Source: Eur Respir J 2002; 20: 518-523
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Humbert M., Deng Z., Simonneau G., Barst R.J., Sitbon O., Wolf M., Cuervo N., Moore K.J., Hodge S.E., Knowles J.A., Morse J.H.. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20: 518-523

Member's Comments

No comment yet.

Related content which might interest you: Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation Source: Eur Respir J 2003; 22: 560-562 Year: 2003 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease Source: Eur Respir J 2004; 24: 371-374 Year: 2004 Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females Source: Eur Respir J 2009; 34: 1093-1099 Year: 2009 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Mutations in the bone morphogenic protein receptor 2 promoter in heritable pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017 Year: 2017 BMPR2 mutations and iron metabolism in pulmonary arterial hypertension patients Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD) Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Pulmonary vascular disease: an historical perspective Source: Eur Respir Mon 2012; 57: 1-16 Year: 2012 Pulmonary hypertension associated with benfluorex exposure Source: Eur Respir J 2012; 40: 1164-1172 Year: 2012 Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension Source: Annual Congress 2005 - Scientific year in review Year: 2005 Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects Source: Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016 Year: 2017 First identification of Krüppel-like factor 2 mutation in heritable pulmonary arterial hypertension Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Targeted gene delivery of BMPR2 attenuates pulmonary hypertension Source: Eur Respir J 2012; 39: 329-343 Year: 2012 BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1668-1681 Year: 2016 Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension}, Source: Eur Respir J 2012; 40: 895-904 Year: 2012 NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016